Study Status: RECRUITING
Recruit Status: RECRUITING
Study Type: INTERVENTIONAL
Official Title: Phase I Dose Escalation Study to Evaluate Tolerability and Safety of 225Ac-PSMA I&T in Patients With Metastatic Prostate Cancer
Brief Summary: 225Ac-PSMA I&T is a radiopharmaceutical for therapy of prostate cancer.
PSMA is overexpressed on prostate cancer cells.
Actium-225 is an alpha emitting radionuclide.
When PSMA I&T is labelled with Actium-225, it can be applied as therapy for prostate cancer.